Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF. The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; and Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused primarily on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.
IPO Year: 2018
Exchange: NASDAQ
Website: sutrobio.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/16/2025 | $2.00 | Neutral → Overweight | Piper Sandler |
| 3/17/2025 | Buy → Neutral | H.C. Wainwright | |
| 3/14/2025 | Mkt Outperform → Mkt Perform | Citizens JMP | |
| 3/14/2025 | $8.00 → $2.00 | Outperform → Neutral | Wedbush |
| 3/14/2025 | $11.00 → $1.00 | Buy → Underperform | BofA Securities |
| 5/8/2024 | $12.00 | Buy | BofA Securities |
| 11/9/2023 | $12.00 | Buy | Deutsche Bank |
| 10/6/2023 | $10.00 | Outperform | Oppenheimer |
| 3/21/2023 | $15.00 → $8.00 | Overweight → Equal Weight | Wells Fargo |
| 8/18/2022 | $15.00 | Overweight | Wells Fargo |
Piper Sandler upgraded Sutro Biopharma from Neutral to Overweight and set a new price target of $2.00
H.C. Wainwright downgraded Sutro Biopharma from Buy to Neutral
Citizens JMP downgraded Sutro Biopharma from Mkt Outperform to Mkt Perform
Wedbush downgraded Sutro Biopharma from Outperform to Neutral and set a new price target of $2.00 from $8.00 previously
BofA Securities downgraded Sutro Biopharma from Buy to Underperform and set a new price target of $1.00 from $11.00 previously
BofA Securities initiated coverage of Sutro Biopharma with a rating of Buy and set a new price target of $12.00
Deutsche Bank initiated coverage of Sutro Biopharma with a rating of Buy and set a new price target of $12.00
Oppenheimer initiated coverage of Sutro Biopharma with a rating of Outperform and set a new price target of $10.00
Wells Fargo downgraded Sutro Biopharma from Overweight to Equal Weight and set a new price target of $8.00 from $15.00 previously
Wells Fargo resumed coverage of Sutro Biopharma with a rating of Overweight and set a new price target of $15.00